Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advanced Life Sciences Holdings, Inc.
Advanced Life Sciences Announces Collaboration With UK Ministry of Defence on ALS-886
August 1st, 2008
Advanced Life Sciences Holdings, Inc. (NASDAQ:ADLS), announced that the United Kingdom's Defence Science and Technology Laboratory ("Dstl") will evaluate the developmental compound ALS-886 as a treatment for chemically induced lung injury. ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in reducing and preventing tissue damage in the lungs. Dstl has experience modeling lung injury and will conduct animal efficacy studies to measure the ability of ALS-886 to improve the clinical outcome following lung injury that results from the inhalation of chemicals that damage the lung surface. "While we remain focused on our...
Source: Health Business Week (2008-08-01)
|
